Abstract:A 67-year-old woman presented with a generalised rash associated with weight loss and resting tachycardia. She had a recent diagnosis of diabetes mellitus. Biochemical evaluation revealed elevated levels of circulating glucagon and chromogranin B. Cross-sectional imaging demonstrated a pancreatic lesion and liver metastases, which were octreotide-avid. Biopsy of the liver lesion confirmed a diagnosis of well-differentiated grade 2 pancreatic neuroendocrine tumour, consistent with metastatic glucagonoma. Serial echocardiography commenced 4 years before this diagnosis demonstrated a progressive left ventricular dilatation and dysfunction in the absence of ischaemia, suggestive of glucagonoma-associated dilated cardiomyopathy. Given the severity of the cardiac impairment, surgical management was considered inappropriate and somatostatin analogue therapy was initiated, affecting clinical and biochemical improvement. Serial cross-sectional imaging demonstrated stable disease 2 years after diagnosis. Left ventricular dysfunction persisted, however, despite somatostatin analogue therapy and optimal medical management of cardiac failure. In contrast to previous reports, the case we describe demonstrates that chronic hyperglucagonaemia may lead to irreversible left ventricular compromise. Management of glucagonoma therefore requires careful and serial evaluation of cardiac status. Learning points: In rare cases, glucagonoma may present with cardiac failure as the dominant feature. Significant cardiac impairment may occur in the absence of other features of glucagonoma syndrome due to subclinical chronic hyperglucagonaemia. A diagnosis of glucagonoma should be considered in patients with non-ischaemic cardiomyopathy, particularly those with other features of glucagonoma syndrome. Cardiac impairment due to glucagonoma may not respond to somatostatin analogue therapy, even in the context of biochemical improvement. All patients with a new diagnosis of glucagonoma should be assessed clinically for evidence of cardiac failure and, if present, a baseline transthoracic echocardiogram should be performed. In the presence of cardiac impairment these patients should be managed by an experienced cardiologist.

A Retrospective Study of 14 Cases of Glucagonoma with Literature Review

Glucagonoma and Glucagonoma Syndrome: One Center's Experience of Six Cases.

Diagnosis and comprehensive treatment of a glucagonoma in a patient with residual intrahepatic metastases postoperatively: A case report and literature review

Pancreatic glucagonoma with metastasis followed up for 15 years: A case report

Case report: Surgical treatment and literature review of a recurrent case of glucagonoma

Necrolytic Migratory Erythema is an Important Visual Cutaneous Clue of Glucagonoma

Clinical Experience in Diagnosis and Treatment of Glucagonoma Syndrome

Diagnosis and Treatment of Glucagonoma Syndrome: One Case Report and Review of Literature

Glucagonoma Syndrome: Report of One Case.

Imaging features of glucagonoma syndrome: A case report and review of the literature.

Diagnosis and treatment of insulinoma:analysis of 17 cases

Clinical Treatment of Gastrinoma: A Case Report and Review of the Literature

A Case Report of Adrenal Teratoma: Huge but Easy to Misdiagnose

Misdiagnosed Gastrinoma: A Case Report

Glucagonoma Syndrome with Serous Oligocystic Adenoma: A Rare Case Report.

The Clinical Aspects of Gastrinoma: Report of 17 Cases

The Diagnosis and Treatment of Gastrinoma: Report of 17 Cases.

Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy

Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres)

Diagnosis and treatment of pancreatoblastoma in China.

Asymptomatic Gastric Adenomyoma and Heterotopic Pancreas in a Patient with Pancreatic Cancer: A Case Report and Review of the Literature